financetom
Business
financetom
/
Business
/
JPMorgan eyes space at former Credit Suisse tower in Canary Wharf, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan eyes space at former Credit Suisse tower in Canary Wharf, source says
Jan 28, 2025 5:46 AM

LONDON, Jan 28 (Reuters) - JPMorgan ( JPM ) is in talks

to take overflow office space in Credit Suisse's empty former

offices in Canary Wharf, a source familiar with the matter told

Reuters, having outgrown its own European headquarters nearby.

The Wall Street banking giant has said that all staff must

return to working in the office five days a week from March,

though the source said that negotiations over the extra space

pre-dated that policy shift.

Reuters reported in November that JPMorgan ( JPM ) was assessing its

long-term options for its London base after running out of space

at its tower at 25 Bank Street. Options could include building a

new tower in Canary Wharf, upgrading its existing tower or

moving to the more central City of London.

The source said that renting space at the former Credit

Suisse building at 1 Cabot Square is viewed as an interim

solution.

UBS Group took on the lease of the Credit Suisse

building after acquiring its stricken rival in 2023, later

relocating the staff to its own London office in the City. The

building is owned by the Qatar Investment Authority (QIA).

UBS declined to comment and a QIA representative was not

immediately available for comment.

Bloomberg first reported on the talks, saying that JPMorgan ( JPM )

was looking to rent roughly a third of the available space in

the building.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats
Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats
Sep 17, 2025
08:50 AM EDT, 09/17/2025 (MT Newswires) -- GSK (GSK), Eli Lilly ( LLY ) , Johnson & Johnson ( JNJ ) , and AstraZeneca ( AZN ) are among the pharmaceutical firms that have pledged to invest more than $350 billion in the US amid the Trump administration's tariff threats, The Wall Street Journal reported Wednesday. GSK said Wednesday it...
NioCorp Developments Prices $50 Million Registered Direct Stock Offering; Shares Down Pre-Bell
NioCorp Developments Prices $50 Million Registered Direct Stock Offering; Shares Down Pre-Bell
Sep 17, 2025
08:52 AM EDT, 09/17/2025 (MT Newswires) -- NioCorp Developments ( NB ) said Wednesday that it priced a registered offering of up to 10 million shares at $5 per share, for gross proceeds of about $50 million. The company said net proceeds from the offering are expected to be used for working capital and general corporate purposes, including construction of...
Elicio Therapeutics Says Data Shows 99% of Patients Generated 'Strong' Responses in Phase 2 Cancer Vaccine Trial
Elicio Therapeutics Says Data Shows 99% of Patients Generated 'Strong' Responses in Phase 2 Cancer Vaccine Trial
Sep 17, 2025
08:43 AM EDT, 09/17/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Wednesday that immunogenicity testing data showed that about 99% of evaluable patients who were administered investigational cancer vaccine ELI-002 7P in an ongoing phase 2 trial generated strong T-cell responses, with an average increase of 145.3 times over baseline responses. The results, which showed mKRAS-specific T-cell responses...
Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease
Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease
Sep 17, 2025
08:49 AM EDT, 09/17/2025 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Wednesday said it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). A statement noted the platform includes patents protecting new compositions and methods targeting a novel mechanism of action involving interleukin-32 (IL-32), which is directly implicated in the progression of CKD....
Copyright 2023-2026 - www.financetom.com All Rights Reserved